T1	Pharmacological_substance 0 10	Epirubicin
N1000 	Reference T1 MeSH:D015251	Epirubicin
T2	Pharmacological_substance 11 27	cyclophosphamide
N1001 	Reference T2 MeSH:D003520	cyclophosphamide
T3	Pharmacological_substance 55 64	tamoxifen
N1002 	Reference T3 MeSH:D013629	tamoxifen
T4	Disorder 157 184	node-positive breast cancer
T5	Pharmacological_substance 336 345	tamoxifen
N1003 	Reference T5 MeSH:D013629	tamoxifen
T6	Disorder 426 439	breast cancer
N1 	Reference T6 UMLS:C0006142	breast cancer
T7	Pharmacological_substance 569 578	tamoxifen
N1004 	Reference T7 MeSH:D013629	tamoxifen
T9	Pharmacological_substance 653 663	epirubicin
N1005 	Reference T9 MeSH:D015251	epirubicin
T11	Pharmacological_substance 677 693	cyclophosphamide
N1006 	Reference T11 MeSH:D003520	cyclophosphamide
T14	Disorder 863 876	breast cancer
N2 	Reference T14 UMLS:C0006142	breast cancer
T19	Pharmacological_substance 1339 1348	tamoxifen
N1007 	Reference T19 MeSH:D013629	tamoxifen
T20	Pharmacological_substance 1352 1362	epirubicin
N1008 	Reference T20 MeSH:D015251	epirubicin
T21	Pharmacological_substance 1365 1381	cyclophosphamide
N1009 	Reference T21 MeSH:D003520	cyclophosphamide
T8	Subject 142 156;185 193	postmenopausal patients
T10	Subject 443 466	postmenopausal patients
T12	Subject 468 505	Four-hundred and eighty-five patients
T13	Disorder 511 541	node-positive operable disease
N3 	Reference T13 UMLS:C2316319	node-positive operable disease
N4 	Reference T13 UMLS:C0042571	node-positive operable disease
T15	Subject 755 783	474 fully evaluable patients
T16	Disorder 818 834	second neoplasms
N5 	Reference T16 UMLS:C2939419	second neoplasms
T17	Combination 50 54	plus
T22	Pharmacological_substance 349 361	chemotherapy
N1010 	Reference T22 MeSH:C403362	chemotherapy
N1011 	Reference T22 MeSH:D004113	chemotherapy
N1012 	Reference T22 MeSH:C057647	chemotherapy
T23	Combination 324 332	addition
T25	Speculation_cue 275 281	assess
T27	Pharmacological_substance 636 651	EC chemotherapy
T28	Combination 591 632	concomitantly (CON) or sequentially (SEQ)
T29	Combination 1316 1335	sequential addition
T30	Subject 806 811	eight
T31	Subject 839 841	88
T32	Subject 888 896	48 of 88
T34	Subject 925 933	40 of 88
